subscribeSubscribe
OptiMed Introduces New Service For Treatment-Resistant Depression

OptiMed Introduces New Service For Treatment-Resistant Depression
ACCESSWIRE
12 Jun 2024
Share Share
Johnson & Johnson 1Q Results

Johnson & Johnson 1Q Results
CONTRACT PHARMA
20 May 2024
Share Share
Data Suggests SPRAVATO is More Tolerable and Effective Compared to Quetiapine XR

Data Suggests SPRAVATO is More Tolerable and Effective Compared to Quetiapine XR
GLOBENEWSWIRE
08 Oct 2023
Share Share
FDA Confirms Paragraph IV Patent Litigation for Esketamine Hydrochloride

FDA Confirms Paragraph IV Patent Litigation for Esketamine Hydrochloride
FDA
25 Apr 2023
Share Share
China Approves Sales of Janssen’s Antidepressant

China Approves Sales of Janssen’s Antidepressant
YICAIGLOBAL
22 Apr 2023
Share Share
New Data from the Phase 3b ESCAPE-TRD Study Show that Participants Receiving SPRAVATO Achieved Higher Response and Remission Rates, Increasing Over Time, Compared to those Receiving Quetiapine Extended-Release

New Data from the Phase 3b ESCAPE-TRD Study Show that Participants Receiving SPRAVATO Achieved Higher Response and Remission Rates, Increasing Over Time, Compared to those Receiving Quetiapine Extended-Release
GLOBENEWSWIRE
27 Mar 2023
Share Share
Nasal spray could help prevent depression relapse

Nasal spray could help prevent depression relapse
EUROPEANPHARMACEUTICALREVIEW
28 Nov 2022
Share Share
Janssen’s Phase IIIb major depressive disorder trial meets primary endpoint

Janssen’s Phase IIIb major depressive disorder trial meets primary endpoint
CLINICALTRIALSARENA
24 Nov 2022
Share Share
J&J builds case for Spravato in tough-to-treat depression

J&J builds case for Spravato in tough-to-treat depression
Fraiser Kansteiner FIERCEPHARMA
24 Nov 2022
Share Share
SPRAVATO data from the phase 3b ESCAPE-TRD study demonstrate superior efficacy

SPRAVATO data from the phase 3b ESCAPE-TRD study demonstrate superior efficacy
BUSINESSWIRE
23 Nov 2022
Share Share